Cargando…

Automated [(18)F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination

BACKGROUND: [(18)F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naka, Sadahiro, Watabe, Tadashi, Kurimoto, Kenta, Uemura, Motohide, Soeda, Fumihiko, Neels, Oliver C., Kopka, Klaus, Tatsumi, Mitsuaki, Kato, Hiroki, Nonomura, Norio, Shimosegawa, Eku, Cardinale, Jens, Giesel, Frederik L., Hatazawa, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391460/ https://www.ncbi.nlm.nih.gov/pubmed/32728815 http://dx.doi.org/10.1186/s41181-020-00101-0

Ejemplares similares

High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
por: Watabe, Tadashi, et al.
Publicado: (2021)

Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on (18)F–Prostate-Specific Membrane Antigen–1007 PET/CT
por: Soeda, Fumihiko, et al.
Publicado: (2021)

(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
por: Giesel, Frederik L., et al.
Publicado: (2016)

One-pot and one-step automated radio-synthesis of [(18)F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment
por: Naka, Sadahiro, et al.
Publicado: (2021)

Improved Stability and Practicality for Synthesis of 4-Borono-2-[(18)F]fluoro-l-phenylalanine by Combination of [(18)O]O(2) Single-Use and [(18)F]CH(3)COOF Labeling Agents
por: Naka, Sadahiro, et al.
Publicado: (2022)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

Evaluation of the default-mode network by quantitative (15)O-PET: comparative study between cerebral blood flow and oxygen consumption
por: Aoe, Jo, et al.
Publicado: (2018)

Evaluation of Integrin α(v)β(3) Expression in Murine Xenograft Models: [(68)Ga]Ga-DOTA-C(RGDfK) PET Study with Immunohistochemical Confirmation
por: Mitsuyuki, Kosuke, et al.
Publicado: (2021)

Comparison of the image-derived radioactivity and blood-sample radioactivity for estimating the clinical indicators of the efficacy of boron neutron capture therapy (BNCT): 4-borono-2-(18)F-fluoro-phenylalanine (FBPA) PET study
por: Isohashi, Kayako, et al.
Publicado: (2016)

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
por: Giesel, Frederik L., et al.
Publicado: (2016)

Optimization of [(11)C]methionine PET study: appropriate scan timing and effect of plasma amino acid concentrations on the SUV
por: Isohashi, Kayako, et al.
Publicado: (2013)

Advantages of FBPA PET in evaluating early response of anti-PD-1 immunotherapy in B16F10 melanoma-bearing mice: Comparison to FDG PET
por: Tatsumi, Mitsuaki, et al.
Publicado: (2022)

Practical calculation method to estimate the absolute boron concentration in tissues using (18)F-FBPA PET
por: Watabe, Tadashi, et al.
Publicado: (2017)

Distribution of Intravenously Administered Acetylcholinesterase Inhibitor and Acetylcholinesterase Activity in the Adrenal Gland: (11)C-Donepezil PET Study in the Normal Rat
por: Watabe, Tadashi, et al.
Publicado: (2014)

FBPA PET in boron neutron capture therapy for cancer: prediction of (10)B concentration in the tumor and normal tissue in a rat xenograft model
por: Hanaoka, Kohei, et al.
Publicado: (2014)

Whole-Body Distribution of Donepezil as an Acetylcholinesterase Inhibitor after Oral Administration in Normal Human Subjects: A (11)C-donepezil PET Study
por: Mochida, Ikuko, et al.
Publicado: (2017)

Evaluation of the total distribution volume of (18)F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling
por: Romanov, Victor, et al.
Publicado: (2019)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility
por: Mamlins, E., et al.
Publicado: (2022)

Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria
por: Isohashi, Kayako, et al.
Publicado: (2015)

Oxygen-15 labeled CO(2), O(2), and CO PET in small animals: evaluation using a 3D-mode microPET scanner and impact of reconstruction algorithms
por: Horitsugi, Genki, et al.
Publicado: (2017)

Procedures for the GMP-Compliant Production and Quality Control of [(18)F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer
por: Cardinale, Jens, et al.
Publicado: (2017)

Activated fibroblasts in muscle sarcoidosis revealed by [(18)F]FAPI-74 PET
por: Watabe, Tadashi, et al.
Publicado: (2023)

Simplified Dynamic Phantom for Pediatric Renography: A Description of Instrument and its Performance
por: Kamiya, Takashi, et al.
Publicado: (2019)

Radiolabeled PSMA Inhibitors
por: Neels, Oliver C., et al.
Publicado: (2021)

Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [(18)F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model
por: Kim, Su Bin, et al.
Publicado: (2022)

The current status of prostate cancer treatment and PSMA theranostics
por: Uemura, Motohide, et al.
Publicado: (2023)

Immuno-PET and Targeted α-Therapy Using Anti–Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma
por: Watabe, Tadashi, et al.
Publicado: (2023)

Assessment of Mediastinal Tumors Using SUV(max) and Volumetric Parameters on FDG-PET/CT
por: Morita, Takahiro, et al.
Publicado: (2017)

Intraindividual comparison of [(68) Ga]-Ga-PSMA-11 and [(18)F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis
por: Hoberück, Sebastian, et al.
Publicado: (2021)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

CT-Based Attenuation Correction in Brain SPECT/CT Can Improve the Lesion Detectability of Voxel-Based Statistical Analyses
por: Kato, Hiroki, et al.
Publicado: (2016)

Radiosynthesis of (11)C-phenytoin Using a DEGDEE Solvent for Clinical PET Studies
por: Kanai, Yasukazu, et al.
Publicado: (2018)

Increase in extraction of I-123 iomazenil in patients with chronic cerebral ischemia
por: Kato, Hiroki, et al.
Publicado: (2018)

Intra-Individual Comparison of Physiologic [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007 Uptake in Ganglia in Patients with Prostate Cancer: A Retrospective, Monocentric Analysis
por: Novruzov, Emil, et al.
Publicado: (2023)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_imbkqr3hbc9a981pjanehra9l7